Editorial
It's not too late: a proposal to standardize the terminology of “late-onset” cytomegalovirus infection and disease in solid organ transplant recipients
R.R. Razonable,
E.A. Blumberg,
Corresponding Author
R.R. Razonable
Editor
Division of Infectious Diseases, Department of Medicine and the William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota, USA
Correspondence to:
Raymund R. Razonable, MD, Division of Infectious Diseases, Mayo Clinic, Marian Hall, 5200 First Street SW, Rochester, MN 55905, USA
Tel: 507-284-3747
Fax: 507-255-7767
E-mail: [email protected]
Search for more papers by this authorE.A. Blumberg
Editor
Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Search for more papers by this authorR.R. Razonable,
E.A. Blumberg,
Corresponding Author
R.R. Razonable
Editor
Division of Infectious Diseases, Department of Medicine and the William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota, USA
Correspondence to:
Raymund R. Razonable, MD, Division of Infectious Diseases, Mayo Clinic, Marian Hall, 5200 First Street SW, Rochester, MN 55905, USA
Tel: 507-284-3747
Fax: 507-255-7767
E-mail: [email protected]
Search for more papers by this authorE.A. Blumberg
Editor
Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Search for more papers by this author
References
- 1Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13 (Suppl 4): 93–106.
- 2Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340 (19): 1462–1470.
- 3Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350 (9093): 1729–1733.
- 4Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326 (18): 1182–1186.
- 5Wreghitt TG, Abel SJ, McNeil K, et al. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Transpl Int 1999; 12 (4): 254–260.
- 6Bronsther O, Makowka L, Jaffe R, et al. Occurrence of cytomegalovirus hepatitis in liver transplant patients. J Med Virol 1988; 24 (4): 423–434.
- 7Millett R, Tomita T, Marshall HE, Cohen L, Hannah H 3rd. Cytomegalovirus endomyocarditis in a transplanted heart. A case report with in situ hybridization. Arch Pathol Lab Med 1991; 115 (5): 511–515.
- 8Richardson WP, Colvin RB, Cheeseman SH, et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 1981; 305 (2): 57–63.
- 9Paraskeva M, Bailey M, Levvey BJ, et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011; 11 (10): 2190–2196.
- 10Klassen DK, Drachenberg CB, Papadimitriou JC, et al. CMV allograft pancreatitis: diagnosis, treatment, and histological features. Transplantation 2000; 69 (9): 1968–1971.
- 11Roux A, Mourin G, Fastenackels S, et al. CMV driven CD8(+) T-cell activation is associated with acute rejection in lung transplantation. Clin Immunol 2013; 148 (1): 16–26.
- 12Tu PT, Shu KH, Cheng CH, et al. Universal valganciclovir prophylaxis significantly reduces episodes of first-year cytomegalovirus disease and biopsy-proven acute rejection in kidney transplant recipients. Transplant Proc 2014; 46 (2): 574–577.
- 13Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46 (6): 840–846.
- 14Delgado JF, Reyne AG, de Dios S, et al. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant 2015; 34 (8): 1112–1119.
- 15Milan A, Sampaio AM, Guardia AC, et al. Identification of bacterial infections and clinical manifestation associated with cytomegalovirus in liver transplantation patients. Transplant Proc 2013; 45 (3): 1130–1132.
- 16Fernandez-Sabe N, Cervera C, Lopez-Medrano F, et al. Risk factors, clinical features, and outcomes of listeriosis in solid-organ transplant recipients: a matched case-control study. Clin Infect Dis 2009; 49 (8): 1153–1159.
- 17Sahin SZ, Akalin H, Ersoy A, et al. Invasive fungal infections in renal transplant recipients: epidemiology and risk factors. Mycopathologia 2015; 180 (1–2): 43–50.
- 18Iriart X, Challan Belval T, Fillaux J, et al. Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am J Transplant 2015; 15 (1): 190–199.
- 19Bosch W, Heckman MG, Pungpapong S, Diehl NN, Shalev JA, Hellinger WC. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation 2012; 93 (7): 723–728.
- 20Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176 (6): 1462–1467.
- 21Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20 (5): 1346–1353.
- 22Einollahi B, Motalebi M, Salesi M, Ebrahimi M, Taghipour M. The impact of cytomegalovirus infection on new-onset diabetes mellitus after kidney transplantation: a review on current findings. J Nephropathol 2014; 3 (4): 139–148.
- 23Luan FL, Kommareddi M, Ojo AO. Impact of cytomegalovirus disease in D+/R− kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis. Am J Transplant 2011; 11 (9): 1936–1942.
- 24Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4 (4): 611–620.
- 25Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10 (5): 1228–1237.
- 26Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185 (7): 854–860.
- 27Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 2000; 70 (5): 717–722.
- 28Reischig T, Hribova P, Jindra P, et al. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol 2012; 23 (9): 1588–1597.
- 29Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8 (1): 69–77.
- 30Mumtaz K, Faisal N, Husain S, Morillo A, Renner EL, Shah PS. Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis. Am J Transplant 2015; 15 (2): 472–481.
- 31Florescu DF, Qiu F, Schmidt CM, Kalil AC. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis 2014; 58 (6): 785–803.
- 32Boudreault AA, Xie H, Rakita RM, et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis. Transpl Infect Dis 2011; 13 (3): 244–249.
- 33Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184 (11): 1461–1464.
- 34Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152 (12): 761–769.
- 35Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007; 13 (12): 1703–1709.
- 36Santos CA, Brennan DC, Chapman WC, Fraser VJ, Olsen MA. Delayed-onset cytomegalovirus disease coded during hospital readmission in a multicenter, retrospective cohort of liver transplant recipients. Liver Transpl 2015; 21 (5): 581–590.
- 37Santos CA, Brennan DC, Fraser VJ, Olsen MA. Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation. Transplantation 2014; 98 (2): 187–194.
- 38Linnemann CC, Dunn CR, First MR, Alvira M, Schiff GM. Late onset of fatal cytomegalovirus infection after renal transplantation. Primary or reactivation infection? Arch Intern Med 1978; 138 (8): 1247–1250.
- 39Shibolet O, Ilan Y, Kalish Y, et al. Late cytomegalovirus disease following liver transplantation. Transpl Int 2003; 16 (12): 861–865.
- 40Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001; 33 (7): E62–E68.
- 41Blyth D, Lee I, Sims KD, et al. Risk factors and clinical outcomes of cytomegalovirus disease occurring more than one year post solid organ transplantation. Transpl Infect Dis 2012; 14 (2): 149–155.
- 42Cummins NW, Deziel PJ, Abraham RS, Razonable RR. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation. Transpl Infect Dis 2009; 11 (1): 20–27.
- 43Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56 (6): 817–824.
- 44Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78 (9): 1390–1396.
- 45Schoeppler KE, Lyu DM, Grazia TJ, Crossno JT Jr, Vandervest KM, Zamora MR. Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis? Am J Transplant 2013; 13 (2): 376–382.
- 46Cervera C, Pineda M, Linares L, et al. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients. Transplant Proc 2007; 39 (7): 2228–2230.
- 47Viot B, Garrigue I, Taton B, et al. Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome. Transpl Infect Dis 2015; 17 (4): 497–509.
- 48Ersan S, Yorukoglu K, Sert M, et al. Unusual case of severe late-onset cytomegalovirus-induced hemorrhagic cystitis and ureteritis in a renal transplant patient. Ren Fail 2012; 34 (2): 247–250.
- 49Squires JE, Sisk RA, Balistreri WF, Kohli R. Isolated unilateral cytomegalovirus retinitis: a rare long-term complication after pediatric liver transplantation. Pediatr Transplant 2013; 17 (1): E16–E19.
- 50Eid AJ, Bakri SJ, Kijpittayarit S, Razonable RR. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis 2008; 10 (1): 13–18.
- 51Egli A, Bergamin O, Mullhaupt B, Seebach JD, Mueller NJ, Hirsch HH. Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and review of the literature. Transpl Infect Dis 2008; 10 (1): 27–43.
- 52Boehler A, Schaffner A, Salomon F, Keusch G. Cytomegalovirus disease of late onset following renal transplantation: a potentially fatal entity. Scand J Infect Dis 1994; 26 (4): 369–373.
